SOLTAMOX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOLTAMOX (SOLTAMOX).
Selective estrogen receptor modulator (SERM). Binds to estrogen receptors, competitively inhibiting estrogen binding. In breast tissue, acts as an antagonist; in bone and cardiovascular system, acts as an agonist.
| Metabolism | Primarily metabolized by CYP2D6 and CYP3A4 to active metabolites (e.g., endoxifen, 4-hydroxytamoxifen). Also undergoes glucuronidation via UGT1A4 and UGT2B7. |
| Excretion | Primarily renal (80-90% as unchanged drug); biliary/fecal excretion accounts for 10-20%. |
| Half-life | 24-36 hours in adults; prolonged in renal impairment (up to 96 hours in ESRD). Steady-state reached in ~5 days. |
| Protein binding | 98-99%, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5-0.8 L/kg; indicates extensive tissue distribution, including into breast milk. |
| Bioavailability | Oral: 70-80% (first-pass metabolism minimal). |
| Onset of Action | Oral: 2-4 hours for peak plasma concentration; IV: immediate onset of action. |
| Duration of Action | 24-48 hours based on once-daily dosing; clinical effect persists due to long half-life. |
| Molecular Weight | 300.39 |
300 mg orally once daily for 5 days, starting on day 1 of menses.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR 30-89 mL/min). Not recommended for severe renal impairment (eGFR <30 mL/min) due to lack of data. |
| Liver impairment | Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). Use with caution in moderate hepatic impairment (Child-Pugh class B); dose reduction has not been established. No adjustment needed for mild impairment (Child-Pugh class A). |
| Pediatric use | Not indicated for premenarcheal patients; safety and efficacy not established in children. |
| Geriatric use | No specific dose adjustment recommended; use with caution due to potential age-related renal and hepatic function decline. |
| 1st trimester | Contraindicated due to risk of fetal harm; may cause estrogenic effects. |
| 2nd trimester | Contraindicated due to risk of fetal harm. |
| 3rd trimester | Contraindicated due to risk of fetal harm. |
Clinical note
Comprehensive clinical and safety monograph for SOLTAMOX (SOLTAMOX).
| Placental transfer | Crosses placenta; distributed to fetal tissues. |
| Breastfeeding | Contraindicated; may pass into breast milk and cause serious adverse effects in the infant. |
| Lactation Rating | L5 - Contraindicated |
■ FDA Black Box Warning
WARNING: Serious and life-threatening events associated with tamoxifen include uterine malignancies (endometrial adenocarcinoma, uterine sarcoma), stroke, and pulmonary embolism. The risk increases with duration of use and is higher in patients with certain risk factors. Use only if benefit outweighs risk.
| Serious Effects |
PregnancyBreastfeedingHistory of thromboembolic disordersHepatic adenomaKnown or suspected estrogen-dependent neoplasia
| Precautions | Increased risk of uterine cancer (endometrial cancer, uterine sarcoma); increased risk of thromboembolic events (DVT, PE, stroke); hepatic effects (fatty liver, hepatitis, cholestasis); hypercalcemia in patients with bone metastases; ocular effects (cataracts, retinopathy); fetal harm (pregnancy category D); drug interactions with CYP2D6 inhibitors or inducers. |
| Food/Dietary | Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4, increasing tamoxifen plasma concentrations. No other specific food restrictions. |
Loading safety data…
| Teratogenic Risk |
| SOLTAMOX (tamoxifen) is contraindicated in pregnancy (FDA Pregnancy Category D). First trimester exposure is associated with fetal anomalies including craniofacial defects, genital tract abnormalities, and developmental delay. Second and third trimester exposure may increase risk of spontaneous abortion, premature birth, and low birth weight. Animal studies show teratogenicity at doses lower than human therapeutic doses. |
| Fetal Monitoring | If pregnancy occurs during treatment, immediate discontinuation and fetal assessment are required. Regular monitoring includes: pregnancy test prior to initiation and monthly during therapy; ultrasonography for fetal anatomy if exposure occurs; monitoring for signs of fetal distress or growth restriction. Maternal monitoring for thromboembolic events, hepatic effects, and endometrial changes is also necessary. |
| Fertility Effects | Tamoxifen may induce ovulation and increase fertility in premenopausal women due to its antiestrogenic effects on the hypothalamus-pituitary axis. Long-term use may cause ovarian cysts, infertility from premature ovarian failure (especially in younger women), and menstrual irregularities. In men, tamoxifen can impair spermatogenesis and reduce fertility. |
| Clinical Pearls | SOLTAMOX (tamoxifen citrate) is a selective estrogen receptor modulator (SERM) used for adjuvant treatment of hormone receptor-positive breast cancer. Monitor for endometrial changes, including hyperplasia and malignancy, with annual gynecological exams. Assess for thromboembolic events, especially in patients with history or risk factors. Consider CYP2D6 genotype to guide dosing; poor metabolizers may require dose adjustment. Avoid concurrent use with strong CYP2D6 inhibitors like paroxetine. Use with caution in patients with leukopenia or thrombocytopenia; obtain baseline CBC and monitor periodically. |
| Patient Advice | Take tamoxifen exactly as prescribed, usually once daily with or without food. · Report any new or unusual vaginal bleeding, pelvic pain, or menstrual irregularities promptly. · Notify your doctor immediately if you experience leg swelling, chest pain, shortness of breath, or sudden vision changes (signs of blood clots). · Use effective non-hormonal contraception during treatment and for 2 months after stopping, as tamoxifen can cause fetal harm. · Avoid grapefruit and grapefruit juice as they may increase tamoxifen levels and risk of side effects. · Inform all healthcare providers that you are taking tamoxifen, especially before any surgery or dental procedure. · Do not stop or change the dose without consulting your doctor. |